PMC:6723065 / 25430-26364 JSONTXT

{"project":"2_test","denotations":[{"id":"31434341-2508608-7278298","span":{"begin":248,"end":250},"obj":"2508608"},{"id":"31434341-19776408-7278299","span":{"begin":657,"end":659},"obj":"19776408"}],"text":"2.2.5. Monoamine Oxidase Inhibitors\nMAO-BIs represent the first step in PD treatment in order to prevent disease progression by their neuroprotective properties. In the DATATOP trial (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) [95] Selegiline has shown successful results in order to delay disease progression, which was calculated by the time until the patients needed potent symptomatic dopaminergic therapy. Another MAO-BI, Rasagiline, has been shown to have modest symptomatic benefits although its neuroprotective properties are still debated. In the ADAGIO trial (Attenuation of Disease Progression with Azilect Given Once-Daily) [96], it has been demonstrated that 1 mg dose of Rasagiline seems to slow disease progression. However, in a recent metanalysis, effective neuroprotective role of MAO-BI therapies was controversial and their role in a prodromal or pauci-symptomatic stage of PD is still debated."}